Contract analysis

I. EXECUTIVE SUMMARY This memorandum sets forth the principal tax structuring considerations arising from the proposed exclusive out-license of the pharmaceutical compound designated PPC-4187, known by its international nonproprietary name Penteracitinib (the "Compound"), by Penterra Pharmaceuticals Corp. ("Penterra" or the "Licensor"), a Delaware corporation publicly traded on the Nasdaq Global Select Market under t

1. Withholding Tax on Cross-Border Payments. The application of withholding taxes to royalty payments, milestone payments, and sublicense income pass-through payments flowing from Meridian and its regional subsidiaries in the Asia-Pacific Territory to Penterra in the United States, including analysis of applicable bilateral income tax treaties (or the absence thereof) between the United States and each relevant Terri

2. Characterization of Payments. The proper characterization of the various payment streams under the License Agreement — specifically, whether such payments constitute royalty income, service income, or capital gain for U.S. federal income tax purposes and for purposes of applying foreign withholding tax regimes and treaty provisions.

3. Transfer Pricing — API Supply Arrangement. The transfer pricing analysis applicable to the supply of active pharmaceutical ingredient (API) by Penterra (through its contract manufacturer, Alkerra Manufacturing Inc.) to Meridian at cost plus fifteen percent (15%), including compliance with IRC §482, the Treasury Regulations promulgated thereunder, and the OECD Transfer Pricing Guidelines, as well as corresponding t

4. U.S. Revenue Recognition Under ASC 606. An overview of the accounting treatment considerations under Accounting Standards Codification Topic 606, Revenue from Contracts with Customers, as applied to the milestone payments, upfront license fee, and royalty streams, to the extent such accounting treatment may affect or be affected by the tax structuring of the transaction.

5. Value-Added Tax and Goods and Services Tax. The application of value-added tax ("VAT") and goods and services tax ("GST") in Territory jurisdictions to cross-border royalty payments, milestone payments, and the importation of API supplies.

6. Structuring Recommendations. Specific recommendations for structuring the payment flows under the License Agreement to optimize tax efficiency for Penterra, including recommendations regarding payment routing through Hong Kong, withholding tax gross-up provisions, FDII deduction eligibility under IRC §250, and foreign tax credit planning. We note at the outset that Penterra's Chief Financial Officer, Garrett T. Ho

II. TRANSACTION STRUCTURE AND PAYMENT FLOWS A. Parties and Corporate Structure The proposed transaction involves the following principal parties and entities: Licensor. Penterra Pharmaceuticals Corp., a corporation organized and existing under the laws of the State of Delaware and headquartered in Princeton, New Jersey. Penterra is a publicly traded company listed on the Nasdaq Global Select Market (ticker: PNTR), wi

III. WITHHOLDING TAX ANALYSIS The cross-border nature of the transaction creates potential withholding tax exposure on royalty payments, milestone payments, and sublicense income pass-through payments flowing from the Territory to the United States. The withholding tax consequences depend on (i) the jurisdiction from which the payment originates, (ii) the existence and terms of any bilateral income tax treaty between

IV. CHARACTERIZATION OF PAYMENTS The tax treatment of each payment stream under the License Agreement depends in the first instance on the proper characterization of the payment for U.S. federal income tax purposes and for purposes of the withholding tax regimes of the Territory jurisdictions. Different characterizations may result in materially different tax consequences, including differences in the applicable with

1. Contingent Royalties / Supplemental License Fees. To the extent the milestones are tied to the value of the license and represent additional consideration for the grant of the exclusive rights — payable upon the occurrence of events that increase the value of the licensed rights to Meridian — they are properly characterized as contingent royalty payments or supplemental license fees. This is the most natural chara

2. Fees for Services. To the extent any milestone payments are tied to specific performance obligations of Penterra — for example, if Penterra is providing development services or technology transfer activities that contribute to the achievement of the milestone — there could be an argument that some portion of the milestone payment represents compensation for services rendered. However, under the current License Agr

3. Other Income. In certain treaty contexts, milestone payments that do not fit neatly within the definition of "royalties" under the applicable income tax treaty may be classified as "other income" under the residual article (typically Article 21 or equivalent). In most U.S. treaties, "other income" is taxable only in the state of residence of the recipient, meaning that Penterra — as a U.S. resident — would not be

V. TRANSFER PRICING — API SUPPLY ARRANGEMENT A. Overview of Supply Terms Under the ancillary Supply Agreement, Penterra will supply the active pharmaceutical ingredient PPC-4187 API and associated reference standards to Meridian (or its designated purchasing affiliate) for an initial term of three (3) years following the Effective Date of the License Agreement. The supply price is calculated on a cost-plus basis, wit

1. Functional Analysis. A detailed description of the functions performed, assets employed, and risks assumed by Penterra (and its contract manufacturer Alkerra) in connection with the API supply, as well as the functions, assets, and risks of the purchaser (Meridian).

2. Method Selection. A discussion of the selection and application of the cost-plus method as the most appropriate transfer pricing method for the API supply arrangement, including an explanation of why other methods (such as the comparable uncontrolled price method or the transactional net margin method) were considered but not selected.

3. Benchmark Study. An economic analysis utilizing comparable uncontrolled transactions to establish the arm's-length range of cost-plus markups for pharmaceutical API supply, including identification and screening of comparable companies or transactions, rejection criteria, and statistical analysis of the resulting interquartile range.

4. Economic Analysis. A quantitative demonstration that the fifteen percent (15%) markup falls within the arm's-length range, including computation of the actual cost base, the markup, and the resulting transfer price for the relevant fiscal year. C. PRC Transfer Pricing Considerations Meridian Pharma (Shanghai) Co., Ltd., as a PRC wholly foreign-owned enterprise, is subject to the transfer pricing rules of the Peopl